Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.

Saved in:
Bibliographic Details
Title: Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Authors: Bolton AE; Novartis Pharma AG, Basel, Switzerland. ann.bolton@pharma.novartis.com, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M
Source: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2004 Feb; Vol. 53 (2), pp. 102-6. Date of Electronic Publication: 2003 Nov 07.
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0344-5704 (Print) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:0344-5704
DOI:10.1007/s00280-003-0722-9